 June 9, 2020 - ObsEva SA NASDAQ: OBSV SIX: OBSN, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a womans reproductive health and pregnancy, today announced that shareholders approved all Board proposals at its 2020 Annual General Meeting held on June 9, 2020. To access the general meetings section of the Companys website, please click here. 